Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$18.78 USD
+0.46 (2.51%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $18.98 +0.20 (1.06%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.78 USD
+0.46 (2.51%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $18.98 +0.20 (1.06%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Zacks News
NVO Stock Down on Unsatisfactory Data From Mid-Stage Obesity Study
by Zacks Equity Research
Novo Nordisk stock falls 5.5% on unsatisfactory safety and efficacy data from a mid-stage study of investigational obesity candidate, monlunabant.
Wall Street Analysts Think Corbus Pharmaceuticals (CRBP) Could Surge 43.82%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 43.8% in Corbus Pharmaceuticals (CRBP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's Why
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Corbus Pharmaceuticals (CRBP) Could Rally 54.24%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 54.2% upside potential for Corbus Pharmaceuticals (CRBP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price Strength
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
What Makes Corbus Pharmaceuticals (CRBP) a Good Fit for 'Trend Investing'
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Corbus Pharmaceuticals (CRBP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Is Alpine Immune Sciences (ALPN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Alpine Immune Sciences, Inc. (ALPN) and Corbus Pharmaceuticals (CRBP) have performed compared to their sector so far this year.
Is Corbus Pharmaceuticals (CRBP) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Corbus Pharmaceuticals (CRBP) and CVRx (CVRX) have performed compared to their sector so far this year.
Are Medical Stocks Lagging HealthEquity (HQY) This Year?
by Zacks Equity Research
Here is how HealthEquity (HQY) and Corbus Pharmaceuticals (CRBP) have performed compared to their sector so far this year.
Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of -16.67% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -12.50% and 3.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Nektar Therapeutics (NKTR) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 15.84% and 7.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Corbus Pharmaceuticals (CRBP) delivered earnings and revenue surprises of 11.11% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Corcept's (CORT) Q1 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Corcept's (CORT) earnings as well as revenues miss estimates in the first quarter of 2022.
Pacira's (PCRX) Q1 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) earnings fall shy of estimates in the first quarter of 2022 while revenues beat the same.
Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis' (ZTS) earnings and revenues trump estimates in the first quarter of 2022.
AlloVir (ALVR) Up on Third RMAT Status From FDA for Posoleucel
by Zacks Equity Research
The FDA bestows a third Regenerative Medicine Advanced Therapy designation to AlloVir's (ALVR) lead candidate, posoleucel, for preventing life-threatening infections from six viruses. Shares rise.
Citius (CTXR) Posts Top-Line Data From Pivotal Lymphoma Study
by Zacks Equity Research
Citius (CTXR) releases encouraging top-line data from the phase III study on I/ONTAK for the treatment of persistent or recurrent cutaneous T-cell lymphoma.
Corcept (CORT) Posts OS Data from Phase II Ovarian Cancer Study
by Zacks Equity Research
Corcept (CORT) posts overall survival data from a phase II study evaluating relacorilant plus nab-paclitaxel for treating recurrent platinum-resistant ovarian cancer.
AlloVir (ALVR) Begins Study to Prevent Six Viral Infections
by Zacks Equity Research
AlloVir (ALVR) starts a phase III study on its lead candidate, posoleucel, for the prevention of life-threatening viral infections from six common viruses. Shares up.
Zacks.com featured highlights include Carter's, Target Hospitality, iQIYI, The Buckle, and Corbus Pharmaceuticals
by Zacks Equity Research
Carter's, Target Hospitality, iQIYI, The Buckle, and Corbus Pharmaceuticals are part of today's Screen of the Week blog.
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks including CRI, TH, IQ, BKE and CRBP with increasing P/E ratios.
Is it the Right Time to Add Mednax (MD) Stock to Your Kitty?
by Zacks Equity Research
Growing revenues, numerous acquisitions, diversified care network and adequate cash generation abilities are likely to continue driving Mednax (MD).
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -2.70% and 12.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold Onto Acadia Healthcare (ACHC) Now
by Zacks Equity Research
Acadia Healthcare (ACHC) is poised for growth due to higher revenues driven by solid demand for behavioral health services, multiple JVs with established healthcare systems and debt repayment efforts.